How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,092 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

361. A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults

), or injectable progesterone (Depo-Provera®, Pfizer Inc., or equivalent) double barrier methods (condoms, cervical cap, diaphragm, and vaginal contraceptive film with spermicide) intrauterine device (IUD) with a low failure rate defined as less than 1% per year monogamous with a vasectomized male partner or same-sex female partner or is of childbearing potential and not sexually active, has a negative serum pregnancy test, and is willing to commit to using a consistent and acceptable method of birth control

2014 Clinical Trials

362. Butrans for Treatment of Restless Legs Syndrome

accepted method of birth control. Acceptable forms of birth control include: Condom + spermicide Diaphragm + spermicide Oral contraceptive pills, hormone implants (like Norplant), or injections(like Depo-Provera) Intrauterine Device Exclusion Criteria: Lifetime history of DSM-IVopiod, alcohol, or other substance abuse. History of opioid treatment for RLS with inadequate response Positive urine toxicology screen at visit 1. Another chronic pain syndrome that would, in the opinion of the investigator

2014 Clinical Trials

363. Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZâ„¢)

potential using an acceptable method of birth control for a period of 35 days before the first dosing, and females must have a negative pregnancy test at the screening and baseline visits; Note 1: Acceptable methods of birth control include any one of the following: abstinence, vasectomized sexual partner, hormonal methods (i.e. pill, hormonal IUD, Depo-Provera, implants, patch, intravaginal device [NuvaRing]), intrauterine device (IUD [copper banded coils]), diaphragm, cervical cap, or condom

2014 Clinical Trials

364. HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC

fight infections that have started. Immune cells are also the type of cells that HIV (human immunodeficiency virus) infects so understanding more about them will help to better understand how to prevent the spread of HIV. Immune cells will be studied from the reproductive tract of women who want to start using one of the following contraceptives: Depo-Provera (DMPA), NET-EN, MPA/E2 (Cyclofem®), the levonorgestrel subdermal implant (Jadelle® ), the etonogestrel subdermal implant (Implanon®

2014 Clinical Trials

365. Cross-over Study of the Efficacy and Safety of SierraSil Joint Formula 14 in Osteoarthritis of the Knee

ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation). OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant

2014 Clinical Trials

366. Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream

ingredients Women of childbearing potential must be willing to use a form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g., condom and spermicide) and abstinence. Exclusion Criteria: immunocompromised patients, or subjects with extensive disease that could not reasonably be controlled with topical therapy history or evidence of other conditions

2014 Clinical Trials

367. A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities

) or higher than 90 kg (198 pounds) Participant must be a non-smoker Exclusion Criteria: Participants have a levonorgestrel implant (for example, Norplant) in place or removed within the 30 days before admission to the study site Contraindications to combined hormonal contraceptives Participants who received medroxyprogesterone injection (for example, Depo Provera) within 6 months of admission to the study Use of any other hormonal contraceptive within 30 days of admission to the study site Participants

2014 Clinical Trials

368. Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women

administered every 13 weeks Other Names: Depo provera DMPA injectable contraception Active Comparator: Progestin Implant (Jadelle) Half of women will be randomized to receive progestin implant. Drug: Progestin Contraceptive (Jadelle) 2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years Other Names: Jadelle Contraceptive Implant Outcome Measures Go to Primary Outcome Measures : HIV viral load in the genital tract of HIV-infected women before and after initiation (...) Drug: Depo-Medroxyprogesterone Acetate Drug: Progestin Contraceptive (Jadelle) Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 131 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Other Official Title: A Randomized Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women Actual Study

2014 Clinical Trials

369. Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome-Constipation (IBS-C)

. Positive pregnancy test in women of child-bearing potential. Pregnant or breast-feeding or planning on becoming pregnant. Women of child-bearing potential not using effective contraception. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Intrauterine devices Vasectomy of partner (shown

2014 Clinical Trials

370. Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects

A known or suspected hypersensitivity to any of the trial medications or their excipients or any other NSAIDs (Non-Steroid Anti-Inflammatory Drug) A history of gastrointestinal ulcer, perforation or bleeding A history of cerebrovascular bleeding or any other bleeding disorder Women of childbearing potential not using adequate contraception (e.g, intrauterine device, contraceptive pills, Depo-Provera® implant, barrier device) for at least 3 months prior to, and for the duration of trial participation

2014 Clinical Trials

371. Does Meal Timing Affect Energy Expenditure

, lung or nervous system disease Have stomach or intestinal problems Regularly use medications such as steroids, beta blockers, adrenergic-stimulating agents, and laxatives Take any medications or supplements known to affect sleep, circadian rhythms, or metabolism (with the exception that certain forms of birth control are allowed) Have abnormal lab work that is clinically significant in the opinion of the study physician Are pregnant or lactating Take the Depo Provera shot, or use an Interuterine

2014 Clinical Trials

372. Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers

a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and 60 days after completion/termination of the trial Are breast-feeding Use any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 0 and for the duration of the study. Due to long half-life, subjects using Depo-Provera® within 6 months prior to Day 1 are excluded from participation in this study Use of hormone

2014 Clinical Trials

373. Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and 60 days after completion/termination of the trial Are breast-feeding. Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to Day 1 and for the duration of the study. Due to long half-life, subjects using Depo-Provera® within six months prior to Day 1 will be excluded from participation in this study Use of hormone replacement therapy

2014 Clinical Trials

374. Naproxen Sodium/ASA Platelet Study

., oral or patch contraceptives, intrauterine device, Depo-Provera®, or a double barrier and have a negative pregnancy test at Screening and immediately prior to investigational product administration on Day 1 and Day 6. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy Results of screening and clinical laboratory tests are within normal range or considered not clinically significant by the Principal Investigator

2014 Clinical Trials

375. A Randomized Multi-centre Study to Assess the Safety and Manageability of a Laparoscopic Adhesion Barrier in Women Undergoing Gynecologic Laparoscopic Surgery Followed by Second Look Laparoscopy

with the exception of basal cell carcinoma, have known allergy to dextran, PEG, or FD&C Blue #1, be scheduled to undergo concomitant non-gynaecological surgery, be currently pregnant (including ectopic pregnancy), have received GNRH agonist/antagonist, Depo Provera, danocrine, ulipristal acetate or similar treatment (except oral contraceptives - and including progesterone only) in the 4 weeks prior to study, on pre-operative imaging have Largest fibroid < 2 cms Or largest fibroid > 10 cms diameter intramural

2014 Clinical Trials

376. Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

pregnant for the duration of the study. Participants in whom pregnancy is biologically possible must use at least 2 study approved methods of contraception, one of which must be a barrier method, and must continue contraception until 5 months after stopping the study drug: Male or female condoms with a spermicide, Diaphragm or cervical cap with spermicide, Intrauterine device, Contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive, Male partner with vasectomy

2014 Clinical Trials

377. Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

of 0 or 1 including patients who are not surgical candidates due to comorbid conditions. Peripheral neuropathy: must be < grade 1 Women of childbearing potential must have a negative pregnancy test. All patients of childbearing potential must be willing to consent to using effective contraception, i.e., intrauterine device (IUD), Birth control pills, Depo-Provera, and condoms while on treatment and for 3 months after their participation in the study ends. No experimental intravesical therapy within

2014 Clinical Trials

378. A Phase I Study to Evaluate the PK and PD of a Single Injection of Levonorgestrel Butanoate for Female Contraception

at screening for these subjects Use of an injectable hormonal contraceptive (Depo-Provera®) within the past 10 months Use of oral contraceptives, contraceptive implants, or other sex steroid hormones within 30 days prior to screening visit Women who are breastfeeding or within 30 days of discontinuing breast feeding Women planning to undergo major surgery within four months of study enrollment Women planning pregnancy within their months of study enrollment Smoking in women who are ages 18-44 years old

2014 Clinical Trials

379. Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

Criteria: Healthy adults (male or non-pregnant, non-lactating female) 18 to 50 years of age (inclusive) at the time of screening If the subject is female, Non-childbearing potential (ie, either surgically sterilized or one year post-menopausal), abstinent or using adequate contraceptive precautions (eg, intrauterine contraceptive device; oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream or foam; Norplant® or Depo-Provera®) during this study and must agree

2014 Clinical Trials

380. Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

per day or 20 mg every other day Patients who are being treated with monamine oxidase inhibitors or tricyclic antidepressants Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e. oral or injectable eg Depo-Provera or Noristerat contraceptives, intrauterine devices, diaphragm plus spermicide or subdermal implants eg: Norplant®) Patients with, in the opinion of the investigator, a history of and/or active significant alcohol or drug

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>